Minggao Shi

9.8k total citations · 2 hit papers
44 papers, 3.3k citations indexed

About

Minggao Shi is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Minggao Shi has authored 44 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Cardiology and Cardiovascular Medicine, 12 papers in Internal Medicine and 4 papers in Surgery. Recurrent topics in Minggao Shi's work include Atrial Fibrillation Management and Outcomes (32 papers), Cardiac Arrhythmias and Treatments (18 papers) and Venous Thromboembolism Diagnosis and Management (12 papers). Minggao Shi is often cited by papers focused on Atrial Fibrillation Management and Outcomes (32 papers), Cardiac Arrhythmias and Treatments (18 papers) and Venous Thromboembolism Diagnosis and Management (12 papers). Minggao Shi collaborates with scholars based in United States, Germany and Italy. Minggao Shi's co-authors include Michele Mercuri, Robert P. Giugliano, Elliott M. Antman, Christian T. Ruff, Jeanne Mendell, Eugene Braunwald, Indravadan Patel, George Zhang, Gary E. Raskob and Jeffrey I. Weitz and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Minggao Shi

44 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

2017 1.1k citations Gary E. Raskob, Michele Mercuri et al. profile →
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

2015 299 citations Christian T. Ruff, Robert P. Giugliano et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minggao Shi United States	24	2.7k	2.0k	341	306	256	44	3.3k
Isabelle Mahé France	27	1.5k 0.6×	1.3k 0.7×	385 1.1×	326 1.1×	224 0.9×	171	2.4k
David Baanstra United States	8	2.5k 0.9×	2.3k 1.2×	828 2.4×	209 0.7×	273 1.1×	9	3.9k
Alexander G.G. Turpie Canada	18	2.7k 1.0×	2.8k 1.4×	889 2.6×	483 1.6×	301 1.2×	48	3.7k
Theodore E. Spiro United States	29	2.3k 0.9×	2.5k 1.2×	879 2.6×	218 0.7×	217 0.8×	66	3.4k
Marcel M.C. Hovens Netherlands	21	1.2k 0.5×	1.1k 0.6×	495 1.5×	179 0.6×	287 1.1×	50	2.0k
Ramón Lecumberri Spain	27	1.2k 0.4×	1.6k 0.8×	374 1.1×	339 1.1×	195 0.8×	110	2.3k
Alejandro Lazo‐Langner Canada	29	1.0k 0.4×	1.6k 0.8×	588 1.7×	372 1.2×	291 1.1×	169	3.2k
Patrick Mismetti France	33	2.2k 0.8×	2.9k 1.4×	1.0k 3.1×	843 2.8×	334 1.3×	154	4.2k
Rohan Hettiarachchi Netherlands	12	1.9k 0.7×	2.0k 1.0×	630 1.8×	144 0.5×	89 0.3×	12	2.5k
Timothy Brighton Australia	23	1.8k 0.7×	2.2k 1.1×	732 2.1×	183 0.6×	212 0.8×	58	3.4k

Countries citing papers authored by Minggao Shi

Since Specialization

Citations

This map shows the geographic impact of Minggao Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minggao Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minggao Shi more than expected).

Fields of papers citing papers by Minggao Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minggao Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minggao Shi. The network helps show where Minggao Shi may publish in the future.

Co-authorship network of co-authors of Minggao Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Minggao Shi. A scholar is included among the top collaborators of Minggao Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minggao Shi. Minggao Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mieghem, Nicolas M. Van, Martin Unverdorben, Marco Valgimigli, et al.. (2018). Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial. American Heart Journal. 205. 63–69. 46 indexed citations

Boriani, Giuseppe, Christian T. Ruff, Julia Kuder, et al.. (2018). Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. European Heart Journal. 40(19). 1541–1550. 87 indexed citations

Mieghem, Nicolas M. Van, Marco Valgimigli, Roxana Mehran, et al.. (2017). TCT-397 Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial. Journal of the American College of Cardiology. 70(18). B163–B163. 1 indexed citations

Magnani, Giulia, Robert P. Giugliano, Christian T. Ruff, et al.. (2016). Efficacy and Safety of Edoxaban Compared with Warfarin in Patients with Atrial Fibrillation and Heart Failure: Insights from ENGAGE AF-TIMI 48. European Journal of Heart Failure. 18(9). 1153–1161. 57 indexed citations

Brown, Karen, Dolly A. Parasrampuria, Daniel Weiss, et al.. (2015). The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. Thrombosis Research. 136(4). 825–831. 29 indexed citations

Ruff, Christian T., Robert P. Giugliano, Eugene Braunwald, et al.. (2015). Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 385(9984). 2288–2295. 299 indexed citations breakdown →

O’Donoghue, Michelle L., Christian T. Ruff, Robert P. Giugliano, et al.. (2015). Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. European Heart Journal. 36(23). 1470–1477. 33 indexed citations

Parasrampuria, Dolly A., Jen‐Fue Maa, Victor Dishy, et al.. (2015). Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Clinical Drug Investigation. 36(2). 127–136. 5 indexed citations

Brown, Karen, et al.. (2014). THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN. Journal of the American College of Cardiology. 63(12). A2095–A2095. 4 indexed citations

10.

Ruff, Christian T., Robert P. Giugliano, Eugene Braunwald, et al.. (2014). RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL. Journal of the American College of Cardiology. 63(12). A329–A329. 1 indexed citations

11.

Mendell, Jeanne, Hamim Zahir, Nobuko Matsushima, et al.. (2013). Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. American Journal of Cardiovascular Drugs. 13(5). 331–342. 170 indexed citations

12.

Gupta, Deepak K., Amil M. Shah, Robert P. Giugliano, et al.. (2013). CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY. Journal of the American College of Cardiology. 61(10). E964–E964. 2 indexed citations

13.

Mendell, Jeanne, et al.. (2013). The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. Journal of Cardiovascular Pharmacology. 62(2). 212–221. 39 indexed citations

14.

Mendell, Jeanne, Robert J. Noveck, & Minggao Shi. (2012). Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. Journal of Cardiovascular Pharmacology. 60(4). 335–341. 26 indexed citations

15.

Mendell, Jeanne, Helen Kastrissios, Michelle Green, et al.. (2012). Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thrombosis and Haemostasis. 107(5). 925–934. 107 indexed citations

16.

Mendell, Jeanne, Robert J. Noveck, Frank Lee, et al.. (2011). DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR. Journal of the American College of Cardiology. 57(14). E1510–E1510. 8 indexed citations

17.

Cohen, Alexander T., Bengt I. Eriksson, Dávid Puskás, et al.. (2010). Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. Thrombosis and Haemostasis. 104(9). 642–649. 120 indexed citations

18.

Weinstein, Sharon M., et al.. (2006). Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clinical Therapeutics. 28(1). 86–98. 20 indexed citations

19.

Shi, Minggao, Jeremy M. G. Taylor, John L. Fahey, et al.. (1997). Early Levels of CD4, Neopterin, and β2-Microglobulin Indicate Future Disease Progression. Journal of Clinical Immunology. 17(1). 43–52. 12 indexed citations

20.

Shi, Minggao, et al.. (1996). Models for residual time to AIDS. Lifetime Data Analysis. 2(1). 31–49. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact